Кабазитаксел в лечении метастатического кастрационно-резистентного рака предстательной железы
- Авторы: Огнерубов Н.А.1,2
-
Учреждения:
- ФГБОУ ВО «Тамбовский государственный университет им. Г.Р. Державина»
- ГБУЗ «Тамбовский областной онкологический диспансер»
- Выпуск: Том 23, № 3 (2021)
- Страницы: 477-488
- Раздел: КЛИНИЧЕСКАЯ ОНКОЛОГИЯ
- URL: https://journals.rcsi.science/1815-1434/article/view/83037
- DOI: https://doi.org/10.26442/18151434.2021.3.201201
- ID: 83037
Цитировать
Полный текст
Аннотация
Рак предстательной железы в структуре заболеваемости злокачественными новообразованиями занимает 4-е место, что составляет 7,3%. В 2020 г. в мире было выявлено 1 414 259 новых случаев, за этот же период умерли 375 304 человека. В последние десятилетия отмечается значительный рост числа случаев метастатического кастрационно-резистентного рака предстательной железы (мКРРПЖ). В настоящее время не существует единого мнения по выбору оптимальной тактики лечения. Для этих целей предложены различные лечебные опции. Однако режимы и последовательность их применения являются спорными и далеки от решения. Целью данного обзора является анализ исследований, посвященных применению кабазитаксела в лечении мКРРПЖ. История применения таксанов при распространенном и метастатическом раке предстательной железы берет начало в 2004 г., когда Управление по контролю пищевых продуктов и лекарств в США зарегистрировало доцетаксел в качестве терапии 1-й линии при метастатическом раке предстательной железы. В 2010 г. появился новый таксан II поколения – кабазитаксел, показавший активность при развитии кастрационной резистентности. Он продемонстрировал высокую противоопухолевую активность и значимую эффективность при прогрессировании на фоне лечения доцетакселом и ингибиторами рецепторов андрогена. В настоящее время анализу доступны результаты ряда рандомизированных клинических исследований, посвященных различным аспектам лечебной тактики при мКРРПЖ. Однако их данные и особенно клиническая польза неоднозначны, а порой и противоречивы. В обзоре приведены результаты научных изысканий, международных клинических исследований, касающихся различных аспектов мКРРПЖ, в особенности выбора современной оптимальной лечебной тактики.
Полный текст
Открыть статью на сайте журналаОб авторах
Николай Алексеевич Огнерубов
ФГБОУ ВО «Тамбовский государственный университет им. Г.Р. Державина»; ГБУЗ «Тамбовский областной онкологический диспансер»
Автор, ответственный за переписку.
Email: ognerubov_n.a@mail.ru
ORCID iD: 0000-0003-4045-1247
SPIN-код: 3576-3592
д-р мед. наук, канд. юрид. наук, проф., зав. каф. онкологии, зам. глав. врача по КЭР, засл. работник высшей школы РФ, засл. врач РФ
Россия, ТамбовСписок литературы
- Shiota M, Eto M. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol. 2016;23(5):360-9.
- Sathianathen NJ, Koschel S, Thangasamy IA, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2020;77:365-72. doi: 10.1016/j.eururo.2019.09.004
- Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76-85.
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.
- De Bono JS, Oudard S, Ozguroglu M, et al. Predonisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9794):1147-54.
- Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23.
- Angelergues A, Efstathiou E, Gyftaki R, et al. Results of the FLAC European Database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor-targeted agents. Clin Genitourin Cancer. 2018;16(4):e777-e784.
- Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497-506.
- Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer – PROSELICA. J Clin Oncol. 2017;35(28):3198-206.
- De Wit R, de Bono J, Sternberg CN, et al.; CARD Investigators. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019;381:2506-18. doi: 10.1056/NEJMoa1911206
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660
- Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020 [Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2019 godu. Pod red. AD Kaprina, VV Starinskogo, AO Shakhzadovoi. Moscow: MNIOI im. P.A. Gertsena − filial FGBU “NMITs radiologii” Minzdrava Rossii, 2020 (in Russian)].
- Shore N, Oliver L, Shui I, et al. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations. J Urol. 2021;205(4):977-86. doi: 10.1097/JU.0000000000001570
- Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10:e0139440.
- Morgan C, McEwan P, Chamberlain G, et al. PCN17 castration-resistant prostate cancer (CRPC): A UK epidemiology study. Value in Health. 2010;13:A26. doi: 10.1016/S1098-3015(10)72108-2
- Fuld AD, Young-Xu Y, Li S, et al. Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC). J Clin Oncol. Conf. suppl., 2018; p. 36. doi: 10.1200/JCO.2018.36.15_suppl.e17057
- Hirst CJ, Cabrera C, Kirby M. Epidemiology of castration resistant prostate cancer: A longitudinal analysis using a UK primary care database. Cancer Epidemiol. 2012;36:e349.
- Saad F, Mehra M, Small EJ, et al. A population-based study of the association of prostate-specific antigen doubling time (PSADT) with metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (NMCRPC) patients (PTS). J Urol. 2018;199:e229. doi: 10.1016/j.juro.2018.02.614
- Parihar N. The global forecast of prostate cancer drug-treatable populations eligible for targeted anticancer therapies (2017–2027). Ann Oncol. 2018;29 (Suppl. 3):iii30. doi: 10.1093/annonc/mdy047.080
- Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242-5.
- Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20.
- Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, Phase III study of prednisone and either satraplatin or placebo in patients with castraterefractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431-8.
- Oudard S, Banu E, Medioni J, et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int. 2009;103(12):1641-6.
- Oudard S, Banu E, Scotte F, et al. Prostatespecific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol. 2007;18(11):1828-33.
- Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: Cancer: principle and practice of oncology. Ed. V DeVita, S Hellman, SA Rosenberg. Philadelphia (PA): Lippincott, Williams and Wilkins, 2001; p. 431-51.
- Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2:685-98.
- Sanofi-aventis. XRP6258 investigator’s brochure. Antony (France): Sanofi-aventis, 2000.
- Bart J, Groen HJ, Hendrikse NH, et al. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev. 2000;26:449-62.
- Hunter J, Jepson MA, Tsuruo T, et al. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem. 1993;268:14991-7.
- Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clin Cancer Res. 2009;15(2):723-30. doi: 10.1158/1078-0432.CCR-08-0596
- Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547-52. doi: 10.1093/annonc/mdn171
- Oudard SM, de Bono JS, Ozguroglu M, et al. Cabazitaxel plus prednisone/prednisolone significantly increases overall survival compared to mitoxantrone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results with updated overall survival of a multinational Phase III trial (TROPIC). Ann Oncol. 2010;21 (Suppl. 8):VIII271.
- Schweizer MT, Antonarakis ES. Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl. 2014;16:334-40.
- Center for Drug Evaluation and Research: NDA 20-1023 review: Cabazitaxel. Updated 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/ nda/2010/201023s000Approv.pdf. Accessed: 23.06.2021
- Shiota M, Nakamura M, Yokomizo A, et al. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with >10 cycles of docetaxel chemotherapy: a multi-institutional study. Med Oncol. 2019;36(4):32. doi: 10.1007/s12032-019-1257-1
- Pond GR, Armstrong AJ, Wood BA, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2012;61(2):363-9. doi: 10.1016/j.eururo.2011.06.034
- Kato S, Takai M, Iinuma K, et al. Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer. Scientific World Journal. 2021. Available at: https://www.hindawi.com/journals/tswj/2021/8824140/. Accessed: 27.06.2021
- Sonpavde G, Bhor M, Hennessy D, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer. 2015;13:309-18.
- Maines F, Caffo O, Veccia A, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015;96:498-506.
- Van Soest RJ, van Royen ME, de Morree ES, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer.2013;49:3821-30.
- Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:1198-204.
- Suzuki H, Castellano D, de Bono J, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Jpn J Clin Oncol. 2021;51(8):1287-97. doi: 10.1093/jjco/hyab028
- Suzuki H, Shin T, Fukasawa S, et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Jpn J Clin Oncol. 2020;50:810-20.
- Droz JP, Efstathiou E, Yildirim A, et al. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry. Urol Oncol. 2016;34(5):234.e21-9.
- Matsumoto T, Shiota M, Nakamura M, et al. Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study. Prostate Int. 2021;9(2):96-100.
- Armstrong AJ, Lin P, Higano CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29:2200-7.
- Khalaf DJ, Avilés CM, Azad AA, et al. A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Can Urol Assoc J. 2018;12:E47-E52.
- Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116:11428-36.
- Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol. 2019;20(10):1432-43.
- Loriot Y, Fizazi K, de Bono JS, et al. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer. 2017;123(2):253-62.
- Alumkal JJ, Chowdhury S, Loriot Y, et al. Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with Enzalutamide in the PREVAIL trial. Clin Genitourin Cancer. 2017;15(5):610-17.e3.
- Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2018;73(2):178-211.
- Annala M, Fu S, Bacon JVW, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205.
- Van der Zande K, van der Noort V, Busard M, et al. First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2021;39(15, Suppl.):5059. doi: 10.1200/JCO.2021.39.15_suppl.5059
- Wallis CJD. First Results from a Randomized Phase II Study of Cabazitaxel vs an Androgen Receptor Targeted Agent in Patients with Poor-Prognosis Castration-Resistant Prostate Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting #ASCO21. June, 4–8, 2021.